ArticleThe European respiratory journal2023
Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre study.
Article in The European respiratory journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Recovery of lung function during the first year after COVID-19: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Dual-energy CT based low flow rate, low dose CTPA and lung perfusion in the pulmonary diagnosis of post-COVID-19 syndrome.Frontiers in medicine · 2026Article
- Article
- The post-COVID-19 pulmonary sequelae: manifestations, mechanisms and treatment strategies.Journal of thoracic disease · 2025Review
- Long-term multidimensional patient-centred outcomes after hospitalisation for COVID-19: do not only focus on disease severity.BMJ open respiratory research · 2025Article
- Respiratory burden in post-acute COVID-19 sequelae: a longitudinal study of airway and systemic inflammation and clinical outcomes.ERJ open research · 2025Article
- A comparison of pulmonary function pre and post mild SARS-CoV-2 infection among healthy adults.BMC pulmonary medicine · 2025Observational
- Longitudinal multi-omics analysis of convalescent individuals with respiratory sequelae 6-36 months after COVID-19.BMC medicine · 2025Article
- Observational
- Prolonged corticosteroid therapy and lung abnormalities in patients after severe COVID-19 pneumonia.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Incidence of post-intensive care syndrome among patients admitted to post-ICU multidisciplinary consultations: the retrospective observational PICS-MIR study.Scientific reports · 2024Observational
- Persistent disabilities 28 months after COVID-19 hospitalisation, a prospective cohort study.ERJ open research · 2024Article
- Long-term effect of corticosteroid treatment during acute COVID-19 infection on pulmonary function test results.Journal of thoracic disease · 2024Article
- Factors associated with phenotypes of dyspnea in post-COVID-19 condition: a cross-sectional study.Scientific reports · 2024Article
- Review
- Short- and Long-Term Chest-CT Findings after Recovery from COVID-19: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2024Review
- MicroRNA-centered theranostics for pulmoprotection in critical COVID-19.Molecular therapy. Nucleic acids · 2024Article
- Six and twelve-month respiratory outcomes in a cohort of severe and critical COVID-19 survivors: A prospective monocentric study in Latin America.SAGE open medicine · 2024Article
- Chronic Lung Injury after COVID-19 Pneumonia: Clinical, Radiologic, and Histopathologic Perspectives.Radiology · 2024Review
- Investigating the trajectory of post-COVID impairments: a longitudinal study in Sweden.Frontiers in psychology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
46 authors at 15 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurvivors of severe-to-critical coronavirus disease 2019 (COVID-19) may have functional impairment, radiological sequelae and persistent symptoms requiring prolonged follow-up. This pragmatic study aimed to describe their clinical follow-up and determine their respiratory recovery trajectories, and the factors that could influence them and their health-related quality of life.
methodsAdults hospitalised for severe-to-critical COVID-19 were evaluated at 3 months and up to 12 months post-hospital discharge in this prospective, multicentre, cohort study.
resultsAmong 485 enrolled participants, 293 (60%) were reassessed at 6 months and 163 (35%) at 12 months; 89 (51%) and 47 (27%) of the 173 participants initially managed with standard oxygen were reassessed at 6 and 12 months, respectively. At 3 months, 34%, 70% and 56% of the participants had a restrictive lung defect, impaired diffusing capacity of the lung for carbon monoxide (
conclusionsAlthough pulmonary function and radiological abnormalities improved up to 1 year post-acute COVID-19, high percentages of severe-to-critical disease survivors, including a notable proportion of those managed with standard oxygen, had significant lung sequelae and residual symptoms justifying prolonged follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.